Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Interleukin-1 beta Mouse ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:IL-1ß, Catabolin
  • Species:Mouse
Please select your region to see available products and prices.
Cat. No. Size Price


RAF049R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Cell culture supernatant

Sample Requirements

50 µl/well

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

7.8–500 pg/ml

Limit of Detection

1.2 pg/ml

Intra-assay (Within-Run)

CV = 4.7%

Inter-assay (Run-to-Run)

CV = 5.7%

Spiking Recovery

77,00%

Dilutation Linearity

109,00%

Summary

Research topic

Animal studies, Cytokines and chemokines and related molecules, Oncology

Summary

Interleukin-1 (IL-1), originally described in 1972 as lymphocyte activating factor (LAF) for its effects on thymocytes, is a polypeptide cytokine with two molecular forms. Both forms appear to mediate identical ranges of biological activity which include synthesis of the acute phase proteins by hepatocytes, chemotaxis of polymorphonucleocytes, and release of polymorphonucleocytes from blood and bone marrow. These effects coined the acronym leukocyte endogenous mediator (LEM). Early researchers also called IL-1ß endogenous pyrogen, and it has been shown to induce fever and is thought to contribute to wasting of muscles (PIF, proteolysis inducing factor). Other activities associated with IL-1 are the induction of Prostaglandin E2 by synovial cells and release of collagenase with resulting destruction of cartilage and bone resorption (catabolin, osteoclast activation factor). In addition, IL-1, has multiple immunological functions including enhancement of IL-2 production by T cells and activation of B-cells (BAF) and thymocytes. A true pleiotrope, IL-1 may have tumoricidal activity via its release of IL-2 and interferon gamma and be indirectly antiviral by stimulating fibroblasts to release interferon beta. In its role as mediator of sepsis, IL-1 has most recently been described as enhancing the growth of virulent E. coli.

References to Summary

References to Interleukin-1 beta

  • Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005 Aug;5 (8):629-40
  • Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006 Sep;25 (3):387-408
  • Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004 Apr;3 (4):330-9
  • Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008 Jan;4 (1):34-42
  • Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-50
  • Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci. 1998 Sep 29;856:1-11
  • Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996 Mar 15;87 (6):2095-147
  • Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. 2004 Aug;4 (4):378-85
  • Eder C. Mechanisms of interleukin-1beta release. Immunobiology. 2009;214 (7):543-53
  • Gursoy UK, Kononen E, Uitto VJ, Pussinen PJ, Hyvarinen K, Suominen-Taipale L, Knuuttila M. Salivary interleukin-1beta concentration and the presence of multiple pathogens in periodontitis. J Clin Periodontol. 2009 Nov;36 (11):922-7
  • Korherr C, Hofmeister R, Wesche H, Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur J Immunol. 1997 Jan;27 (1):262-7
  • Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev. 2011 Aug;22 (4):189-95
  • Maedler K, Dharmadhikari G, Schumann DM, Storling J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther. 2009 Sep;9 (9):1177-88
  • Malawista SE, Duff GW, Atkins E, Cheung HS, McCarty DJ. Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum. 1985 Sep;28 (9):1039-46
  • Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy. 1985 Aug;40 (6):424-9
  • Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, Joosten LA. IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog. 2010 Feb 26;6 (2):e1000661
  • Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol. 2014 Jan;10 (1):44-56
  • Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr 30;356 (6372):768-74
  • Tobon-Arroyave SI, Jaramillo-Gonzalez PE, Isaza-Guzman DM. Correlation between salivary IL-1beta levels and periodontal clinical status. Arch Oral Biol. 2008 Apr;53 (4):346-52
Related Products Documents